Next, a nomogram including LRP1B, pathological-N stage, and adjuvant chemotherapy cycle was established to predict the probabilities of 1-, 2-, and 3-year DFSs in GC patients (Figure 1F). This evidence concerns the gene LRP1B and gastric cancer.